Farah Ammar

Farah Ammar

Auto-generated profile, based on publicly available information

Farah Ammar

Department of Pharmacology and Physiology, University of Maryland, School of Medicine, Baltimore, MD 21201, United States of America

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BCBudha Chatterjee
Budha Chatterjee
CBChristopher T. Boughter
Christopher T. Boughter
KGKatrina Gorga
Katrina Gorga
YOYuko Ohta
Yuko Ohta
CBCarly Blair
Carly Blair
NSNevil J. Singh
Nevil J. Singh
The success of the live attenuated Yellow Fever vaccine (YF17D) that elicits immunity lasting over thirty years has made it a widely used model to understand the generation of durable protection. We compare the early single-cell level transcriptional response in mice to YF17D and an adjuvanted-inactivated, but less effective version (InYF). Within the first week, we identify 70 kinetic patterns in 45 cellular clusters, majority of which discriminate between the two formulations, some in a tissue and sex-specific manner. Intriguingly, differential transcripts fall into two categories, one whose association with YF17D or InYF is maintained even when decoupled from their cell-type of expression and the other where such cell-plus-gene pairing is critical to maintain differential marker status. We demonstrate applications of this resource, by identifying B cells with varied interferon and antigen responsiveness in relation to each vaccine. This high-resolution dataset is amenable to further biomarker discovery and hypothesis generation.

9 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CNCyro von Zuben de Valega Negrao
Cyro von Zuben de Valega Negrao
HHHaley Hendrick
Haley Hendrick
FAFarah Ammar
Farah Ammar
RKRemi V. Klotz
Remi V. Klotz
SDSandra Dias
Sandra Dias
MYMin Yu
Min Yu
Metastasis remains the major cause of cancer-related mortality, and circulating tumor cells (CTCs) are both candidate liquid-biopsy biomarkers and plausible intermediates of metastatic dissemination. Because CTCs are extremely rare in peripheral blood, platform comparisons have often focused solely on recovery. That focus is insufficient for applications that depend on the quality of the recovered material, including single-cell profiling, short-term culture, and functional testing. Here, we compared four CTC isolation approaches: TellDx CTC System, Genesis System, RosetteSep™, and flow cytometry, using spike-in experiments in human blood. Capture efficiency was evaluated across all four platforms; purity was assessed for TellDx, Genesis, and RosetteSep™; and post-isolation GFP signal persistence in culture was assessed for TellDx and Genesis as an exploratory proxy for short-term post-isolation preservation. Under the conditions tested, TellDx showed the highest recovery (88.1% ± 3.7%), followed by Genesis (40.6% ± 12.1%), RosetteSep™ (36.5% ± 9.0%), and flow cytometry (7.6% ± 4.5%). TellDx also showed the highest purity score (3.76), whereas Genesis (2.25) and RosetteSep™ (2.09) did not differ substantially. In the short-term culture assay, TellDx-derived samples retained a higher normalized GFP signal than Genesis-derived samples at 48 h and 72 h. To synthesize these readouts, we propose the Recovery Performance Index (RPI), a composite score integrating recovery, purity, and post-isolation signal persistence. Within this experimental framework, TellDx achieved the highest RPI. These data support two conclusions. First, platform benchmarking for CTC workflows benefits from multidimensional evaluation rather than recovery alone. Second, under this spike-in model and within the specific workflows used here, TellDx performed best among the platforms tested. The principal contribution of this study is therefore the establishment of a practical benchmarking framework that can be expanded in future work using clinical samples, multiple CTC phenotypes, and orthogonal viability assays.